Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Department of Endocrinology and Neurology, Jiulongpo People's Hospital, Chongqing, China.
Front Endocrinol (Lausanne). 2022 May 19;13:876960. doi: 10.3389/fendo.2022.876960. eCollection 2022.
Diabetic nephropathy (DN) is regarded as the leading cause of end-stage renal disease worldwide and lacks novel therapeutic targets. To screen and verify special biomarkers for glomerular injury in patients with DN, fifteen datasets were retrieved from the Gene Expression Omnibus (GEO) database, correspondingly divided into training and testing cohorts and then merged. Using the limma package, 140 differentially expressed genes (DEGs) were screened out between 81 glomerular DN samples and 41 normal ones from the training cohort. With the help of the ConsensusClusterPlus and WGCNA packages, the 81 glomerular DN samples were distinctly divided into two subclusters, and two highly associated modules were identified. By using machine learning algorithms (LASSO, RF, and SVM-RFE) and the Venn diagram, two overlapping genes (PRKAR2B and TGFBI) were finally determined as potential biomarkers, which were further validated in external testing datasets and the HFD/STZ-induced mouse models. Based on the biomarkers, the diagnostic model was developed with reliable predictive ability for diabetic glomerular injury. Enrichment analyses indicated the apparent abnormal immune status in patients with DN, and the two biomarkers played an important role in the immune microenvironment. The identified biomarkers demonstrated a meaningful correlation between the immune cells' infiltration and renal function. In conclusion, two robust genes were identified as diagnostic biomarkers and may serve as potential targets for therapeutics of DN, which were closely associated with multiple immune cells.
糖尿病肾病 (DN) 被认为是全球终末期肾病的主要病因,且缺乏新的治疗靶点。为了筛选和验证 DN 患者肾小球损伤的特殊生物标志物,从基因表达综合数据库 (GEO) 中检索了 15 个数据集,分别对应于训练和测试队列,然后进行合并。使用 limma 包,在训练队列中从 81 个肾小球 DN 样本和 41 个正常样本中筛选出 140 个差异表达基因 (DEGs)。借助 ConsensusClusterPlus 和 WGCNA 包,81 个肾小球 DN 样本明显分为两个亚群,并确定了两个高度关联的模块。通过机器学习算法 (LASSO、RF 和 SVM-RFE) 和 Venn 图,最终确定了两个重叠基因 (PRKAR2B 和 TGFBI) 作为潜在的生物标志物,并在外部测试数据集和 HFD/STZ 诱导的小鼠模型中进行了验证。基于这些生物标志物,开发了具有可靠预测能力的用于诊断糖尿病肾小球损伤的诊断模型。富集分析表明 DN 患者的免疫状态明显异常,这两个生物标志物在免疫微环境中发挥着重要作用。鉴定的生物标志物表明免疫细胞浸润与肾功能之间存在有意义的相关性。总之,两个稳健的基因被鉴定为诊断生物标志物,可能成为 DN 治疗的潜在靶点,它们与多种免疫细胞密切相关。